苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.
小分子酪氨酸激酶抑制剂为治疗EMS带来新的希望。
The small molecule tyrosine kinase inhibitors may bring hope in the future for patient with EMS.
目的：对近年来酪氨酸激酶抑制剂的研究进展作以综述。
Objective: to review the progress in the research of tyrosine kinase inhibitors in recent years.
详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。
The inhibitor of VEGF receptor tyrosine kinase was introduced in detail.
PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用？ ？
Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer?
目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。
Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase (PTK).
结论AG490作为一种酪氨酸激酶抑制剂，能影响正常细胞的功能。
Conclusion As an inhibitor of JAK, AG490 can influence the function of normal cells.
继发性FLT3 - TKD突变与酪氨酸激酶抑制剂治疗失败有关。
Secondary FLT3-TKD mutations are associated with treatment failure with tyrosine kinase inhibitors.
本发明提供了使用抗egfr抗体治疗抗酪氨酸激酶抑制剂的癌症的方法。
The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies.
本文介绍了第一、二代以及新近开发的BCR - ABL酪氨酸激酶抑制剂。
This paper introduces the first, second and some new BCR-ABL tyrosine kinases inhibitors.
本发明涉及治疗抗酪氨酸激酶抑制剂疗法的EGFR介导的疾病，特别是癌症。
The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies.
大量的临床经验：酪氨酸激酶抑制剂治疗患有分化型甲状腺癌的患者：M。D。安德森经验。
Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience.
金雀异黄素是一种天然的酪氨酸激酶抑制剂，可以抑制多种肿瘤细胞的增殖，并诱发细胞凋亡。
Genistein, a natural tyrosine kinase inhibitor, has been reported to inhibit growth and induce apoptosis of various Turner cells.
本文就小分子酪氨酸激酶抑制剂治疗非小细胞肺癌脑转移的机理、临床应用以及治疗失败后的处理等方面作一综述。
The mechanisms, clinical applications of small-molecule tyrosine kinase inhibitors on brain metastasis and therapeutic choice after the failure will be reviewed in this article.
随着小分子酪氨酸激酶抑制剂在非小细胞肺癌治疗上获得成功，陆续有其治疗非小细胞肺癌脑转移及脑膜转移的研究。
With the success of small-molecule tyrosine kinase inhibitors in non-small cell lung cancer, recent clinical researches have shown their activities against brain and leptomeningeal metastases.
PTK787因其对肿瘤抑制的出色疗效、口服生物利用度高等特点而成为VEGF受体酪氨酸激酶抑制剂中的佼佼者。
PTK787 is the most promising VEGF receptor- tyrosine kinase inhibitor in pipeline because of its potency in tumor inhibition and oral bioavailability.
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂，能阻断酪氨酸蛋白激酶信号传导通路，从而促进肿瘤细胞凋亡。
Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
选择最佳的二线酪氨酸激酶抑制剂治疗伊马替尼治疗失败的慢性粒细胞白细胞患者：BCR - ABL突变状态是否真的重要？
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
因此，本研究的目的是调查金雀异黄素，一种蛋白质酪氨酸激酶抑制剂，对有急性或慢性糖尿病炎症小鼠（诱导脲佐菌素）的影响。
Therefore, the aim of this study is to investigate the effects of genistein, a protein tyrosine kinase inhibitor, on acute and chronic inflammation in diabetic mice (induced by streptozotocin).
包括单克隆抗体、酪氨酸激酶抑制剂、融合蛋白、瘤苗在内，以her2为靶点的抗肿瘤治疗研究成为热点，并显示出广阔的应用前景。
Anticancer therapies targeting HER2 have shown promise and become a focus, including monoclonal antibody, tyrosine kinases inhibitor, tumor vaccine, fusion protein.
Rigel的激酶抑制剂，称为fostamatinib，以脾酪氨酸激酶为目标。其主要功能是可以让自身免疫疾病形成大型免疫细胞复合体。
Rigel's kinase inhibitor, called fostamatinib, targets spleen tyrosine kinase, which among other functions enables the formation of the large immune-cell complexes found in autoimmune diseases.
结论CD 117可作为MM的肿瘤相关抗原，也可作为靶向信号转导抑制剂酪氨酸激酶选择性抑制剂应用的有价值的标志。
CONCLUSION: CD117 can be regard as the related tumor antigen of MM, and may be a valuable marker in the use of tyrosine kinase selective inhibitors, which inhibit the signal conduct to the target.
bcrabl；酪氨酸激酶；抑制剂；慢性粒细胞白血病；综述。
BCRABL; tyrosine kinases; inhibitors; chronic myelogenous leukemia; review.
依鲁替尼——首创药物，每天口服一次，布鲁顿酪氨酸激酶（BTK）的共价抑制剂——口服给药之后可快速从浆细胞内清除。
Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO 2013).
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
应用推荐